About this trial
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.
The hospital cohort will enroll approximately1,000 patients with positive melioidosis. Participants will be followed at six time points from admission through one year (post-discharge) to capture acute and recovery-phase outcomes, with clinical data collected on demographics, comorbidities, exposures, treatment, adherence, and outcomes.
For each confirmed case, a healthy control will be recruited within two weeks and matched by age, sex, and village of residence. Controls with no symptoms or history of melioidosis will provide a single blood sample at enrolment and will be followed by telephone at 6 and 12 months.
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
This study is funded by the Wellcome Trust. The grant reference number is 323077/Z/24/Z
Eligibility criteria
Qualifiers
Age ≥20 years
Positive for Burkholderia pseudomallei from any clinical samples
Resident of the study area for at least two years, including the follow-up period
Willing to participate and give informed consent.
Disqualifiers
Current tuberculosis (TB) or TB treatment within the past six months
Documented HIV infection or use of immunosuppressive therapy in the past 12 months
History of melioidosis
Significant acute illness
Trial design
Treatments tested in this trial
- Not listed